Semaglutide Prices Surge Nearly 48%, Reshaping Canadian Group Benefit Drug Spending
GreenShield's latest claims data shows a 47.7% rise in semaglutide costs, signalling that GLP-1 therapies are reshaping employer-sponsored drug plans across Canada as chronic disease management becomes a dominant cost driver.
What happened
GreenShield's most recent drug plan analysis reveals that spending on semaglutide climbed 47.7%, making it one of the fastest-growing line items in Canadian employer-sponsored benefits. The increase reflects the broader entry of GLP-1 therapies into mainstream chronic disease care, particularly for type 2 diabetes and weight management.
What it means for consumers
For plan members, the headline figure translates into real-world consequences at the pharmacy counter and the doctor's office. Patients prescribed semaglutide should expect more scrutiny around prior authorization, step therapy requirements, and ongoing proof of clinical improvement. Those who do not meet renewal criteria may see coverage reduced or terminated, pushing out-of-pocket costs onto individuals who have already adapted their lifestyle and treatment around the medication.
What it means for premiums
No direct premium change has been announced.
Coverage considerations
Group benefit plans are likely to tighten formularies for GLP-1 drugs in the near term. Insurers may narrow the indications they will reimburse, separate diabetes coverage from weight-loss coverage, or cap the duration of continuous use. Plan sponsors should also prepare for broader ripple effects, as rising specialty drug spend often accelerates the trend toward higher deductibles, mandatory generic substitution, and the introduction of chronic disease management programs designed to contain downstream costs.